Ophthalmology

This technology is an optimized CRISPR-Cas12j nuclease for high-efficiency gene editing.

This technology is a pyruvate analog, ethyl pyruvate, that can be used to treat glaucoma and other intraocular pressure (IOP)-related retinal diseases.

This technology is a therapeutic approach that uses a low dose of nicotinamide to lower intraocular pressure (IOP), which, when elevated, is an important risk factor for glaucoma.

This technology is an approach for improved glaucoma risk prediction and treatment that measures the levels of glycolysis-related metabolites.

This technology is a class of small molecule activators of the Bestrophin-1 chloride channel designed to restore retinal function and mitigate vision loss in Best vitelliform macular dystrophy (BVMD).

This technology uses CRISPR-Cas9 gene editing to target prolyl hydroxylase (PHD2) to slow the progression of retinitis pigmentosa (RP).

This technology is a femtosecond laser-based system for modulating cytokine activity in corneal tissues to control inflammation and prevent keratocyte apoptosis.

This technology is a collection of optimized therapeutic prime-editing strategies targeting four common splicing mutations in the peripherin‐2 gene (PRPH2) that are associated with various retinal degenerations.

This technology is a modified CRISPR/Cas9 gene editing therapy that is mutation-independent for treating autosomal dominant disease-related genes, including retinitis pigmentosa.

This technology is an AAV-mediated BEST1 gene therapy for the treatment of retinal degenerative disorders associated with Bestrophin-1 (BEST1) dominant mutations.

This technology is a gene therapy which delivers CRB1 isoforms to their cell-specific localizations, for the treatment of retinopathies caused by CRB1 mutations.

This technology is a generally applicable gene therapy approach that restores metabolic dysregulation and treats retinal degenerative diseases regardless of genetic variation.

This technology is a method of reprogramming cellular metabolism to treat neurodegenerative disorders by downregulating catabolism and upregulating anabolism in cells.

This technology is an artificial intelligence-based platform for improving the quality of images taken from portable OCT devices and detecting age-related macular degeneration.

This technology uses a femtosecond laser to crosslink collagen and can be used as treatment for repair of collagenous tissues such as cornea and cartilage.